Literature DB >> 7657392

Expression of 2 variant forms of fibroblast growth factor receptor 1 in human breast.

Y A Luqmani1, C Mortimer, C Yiangou, C L Johnston, G S Bansal, D Sinnett, M Law, R C Coombes.   

Abstract

The expression of variant mRNAs encoding isoforms of fibroblast growth factor receptor (FGFR)1 with either 2 or 3 Ig-like loops in the extracellular domain was investigated in human breast tissues and cell lines using a polymerase chain reaction amplification method. Almost all tissues contained both forms of FGFR1, but cancers (n = 137) had a significantly lower proportion of the transcript that encoded the full 3-loop form compared with non-malignant biopsies (n = 34). This was confirmed using microdissected populations of normal and cancerous cells from frozen tissue sections. A high ratio of the 2- to 3-loop form was found to be predictive of reduced relapse-free survival. In both groups, however, the predominant form of FGFR1 was that encoding the 2-loop receptor. Cell lines derived from a variety of tissues, including breast, also co-expressed both variants of FGFR1, suggesting their presence within the same cell type. Again, there was a similar preponderance of the shorter isoform. Our results were confirmed at the protein level, where out of 5 cancers analysed 4 expressed more of the 2-loop form than the 3-loop form. Our findings suggest that cells may normally simultaneously express several splice variants of FGFR1, and aberrant expression or a change in their relative amounts (i.e., in malignancy) could contribute to modified responses to either autocrine or paracrine factors.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7657392     DOI: 10.1002/ijc.2910640411

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  17 in total

1.  Expression of the IIIc variant of FGF receptor-1 confers mitogenic responsiveness to heparin and FGF-5 in TAKA-1 pancreatic ductal cells.

Authors:  M Kornmann; M E Lopez; H G Beger; M Korc
Journal:  Int J Pancreatol       Date:  2001

2.  Discovery of novel fibroblast growth factor receptor 1 kinase inhibitors by structure-based virtual screening.

Authors:  Krishna P Ravindranathan; Valsan Mandiyan; Anil R Ekkati; Jae H Bae; Joseph Schlessinger; William L Jorgensen
Journal:  J Med Chem       Date:  2010-02-25       Impact factor: 7.446

3.  Ligand activation of alternatively spliced fibroblast growth factor receptor-1 modulates pancreatic adenocarcinoma cell malignancy.

Authors:  Selwyn M Vickers; Zhi-Qiang Huang; LeeAnn MacMillan-Crow; Jessica S Greendorfer; John A Thompson
Journal:  J Gastrointest Surg       Date:  2002 Jul-Aug       Impact factor: 3.452

Review 4.  Therapeutic potential of manipulating VEGF splice isoforms in oncology.

Authors:  Emma S Rennel; Steven J Harper; David O Bates
Journal:  Future Oncol       Date:  2009-06       Impact factor: 3.404

5.  Altered splicing of FGFR1 is associated with high tumor grade and stage and leads to increased sensitivity to FGF1 in bladder cancer.

Authors:  Darren C Tomlinson; Margaret A Knowles
Journal:  Am J Pathol       Date:  2010-10-01       Impact factor: 4.307

6.  Alternative splicing in oncogenic kinases: from physiological functions to cancer.

Authors:  Sabine Druillennec; Coralie Dorard; Alain Eychène
Journal:  J Nucleic Acids       Date:  2011-10-05

7.  Expression of keratinocyte growth factor and its receptor in human breast cancer.

Authors:  G S Bansal; H C Cox; S Marsh; J J Gomm; C Yiangou; Y Luqmani; R C Coombes; C L Johnston
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

8.  The location of acidic fibroblast growth factor in the breast is dependent on the activity of proteases present in breast cancer tissue.

Authors:  R C Coope; P J Browne; C Yiangou; G S Bansal; J Walters; N Groome; S Shousha; C L Johnston; R C Coombes; J J Gomm
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

9.  Fibroblast growth factor 2 in breast cancer: occurrence and prognostic significance.

Authors:  C Yiangou; J J Gomm; R C Coope; M Law; Y A Luqmani; S Shousha; R C Coombes; C L Johnston
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

10.  Alternative splicing and tumor progression.

Authors:  Claudia Ghigna; Cristina Valacca; Giuseppe Biamonti
Journal:  Curr Genomics       Date:  2008-12       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.